The trial of a $200 million gender discrimination class-action suit against Swiss-owned drug maker Novartis Pharmaceuticals began yesterday with the defense saying the company “makes no claim that we are perfect” but denying that it underpaid women or intentionally promoted them less frequently than men.

“This isn’t a company with a glass ceiling,” defense attorney Richard Schnadig told the jury of six women and four men in the closely watched case.